MSD provides blockbuster drug free of charge for Evaxion's combination trial

US-based pharmaceutical firm MSD has allowed its drug Keytruda to be used for a phase IIb trial conducted by Evaxion. The Danish biotech company will test its own lead candidate against melanoma in combination with MSD's multi-blockbuster drug.
Photo: MSD / PR
Photo: MSD / PR
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN

Before the end of the year, Evaxion will begin its phase IIb trial of its lead candidate EVX-01 against metastatic melanoma in a partnership with US-based MSD.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading